Myeloma 2017 | Exciting improvements in amyloidosis management and treatment

Ashutosh Wechalekar

Key to the treatment of amyloidosis is being able to discern the severity of illness, so that the patient can be prescribed an appropriate therapy course. In this interview, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, discusses the latest advancements in patient risk stratification, new imaging agents to observe amyloid deposits in soft tissues, and novel treatments for the condition. These include the recent monitoring of von Willebrand factor as a prognostic marker, and immunotherapy drugs currently in clinical trials. This video was recorded at the Myeloma 2017 meeting in Edinburgh, UK.

Share this video